27.07.2026

To,

National Stock Exchange of India Limited
"Exchange Plaza",
Bandra-Kurla Complex,
Bandra (East) Mumbai 400 051

BSE Limited
Floor- 25, P J Tower,
Dalal Street,
Mumbai 400 001

SYMBOL:- EPIGRAL

Scrip Code: 543332

Dear Sirs,

Sub.: Press Release on Un-Audited Financial Results – Q1 FY27
Ref.: Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Press Release on Un-Audited Financial Results – Q1 FY27.

The said Press Release is also available at www.epigral.com in the Investor Relations section.

This is for information and records.

Thanking you,

Yours faithfully,

For Epigral Limited

GAURANG GHANSHYAM TRIVEDI
Digitally signed by GAURANG GHANSHYAM TRIVEDI
Date: 2026.07.27 14:11:37 +05'30'

Gaurang Trivedi
Company Secretary & Compliance Officer
M. No. 22307

Epigral Limited's Q1FY27 PAT jumps 25% YOY to ₹ 99 Cr

Epigral to Deploy ₹600 Crore Capex for Epoxy Resin & Formulations and for setting up Multi-Purpose Plant

Ahmedabad, July 27, 2026: Epigral Limited, one of India's leading integrated chemical manufacturers, today announced its financial results for the quarter ended June 30, 2026. The company posted a growth of 25% in PAT for Q1FY27 at ₹ 99 Cr, as compared to ₹ 79 Cr in Q1FY26. The company's quarterly revenue rose by 15% to ₹ 709 Cr as against ₹ 615 Cr recorded in Q1FY26.

Epigral's board approved its entry into the Epoxy Resin and Formulations business with a planned production capacity of 1,25,000 TPA and setting up Multi-Purpose Plant (MPP). The company will undertake the project with an estimated capex investment of approximately ₹600 crore. The company expects to commission both the commercial plant in H2FY28.

The strategic expansion marks Epigral's forward integration into the advanced materials and specialty chemicals segment, supported by strong and growing demand from key user industries including construction, renewable energy, automotive, electronics, infrastructure, marine, aerospace, industrial flooring, and semiconductor applications.

Epoxy Resin is a critical material used in high-performance and quality-driven applications such as windmill blades, fiber reinforced polymers, tile adhesives, industrial coatings, chemical storage systems, electrical insulation, marine structures, and automotive components. Demand for Epoxy Resin in India continues to grow in line with increasing infrastructure development, manufacturing growth, renewable energy investments, and rising adoption of high-performance materials.

The move is strategically significant for Epigral as key raw materials required for manufacturing Epoxy Resin, including Epichlorohydrin (ECH) and Caustic Soda, are already produced within the company's integrated manufacturing complex at Dahej. More than 50% of the raw material value for the proposed project will be sourced internally, further strengthening Epigral's backward integration advantages and operational efficiencies.

Epigral is also setting up a Multi-Purpose Plant (MPP) to manufacture downstream products of the Epichlorohydrin and Chlorotoluenes value chains. The facility is aimed at addressing the growing domestic demand for pharmaceutical and agrochemical intermediates and water treatment chemicals in India.

In line with its phased development approach, Epigral is also establishing a pilot plant facility for Epoxy Resin & Formulations and MPP, expected to be operational by Q2FY27. The pilot facility will help validate product quality, optimise manufacturing processes, and facilitate customer approvals ahead of commercial-scale operations.

Commenting on the results and development, Maulik Patel, Chairman and Managing Director, Epigral Limited, said: *"Epigral delivered steady growth in Q1FY27 despite severe macroeconomic volatility driven by geopolitical tensions in West Asia. The quarter was marked by fluctuations in raw material and finished goods prices, alongside elevated freight costs and shipment delays. Leveraging its diversified product mix, Epigral successfully navigated these headwinds to achieve 15% revenue growth and an EBITDA margin of 25%.*

While geopolitical challenges persist, operating conditions have stabilized. Backed by India's strong economic growth trajectory, management maintains a positive outlook. To drive future diversified growth, the Board approved strategic investments in a new Epoxy Resin & Formulations plant and a Multi-Purpose Plant (MPP). Both expansions will enhance efficiency within Epigral's integrated manufacturing complex by utilizing internal raw materials. Specifically, the Epoxy Resin plant will consume ECH and Caustic Soda, while the MPP will be downstream of Epichlorohydrin and Chlorotoluenes Value Chain.

The Epoxy Resin plant will cater to domestic and global demand across the renewable energy, infrastructure, electronics, automotive, and industrial sectors. Concurrently, the MPP will meet rising domestic demand for pharmaceutical and agrochemical intermediates and water treatment chemicals.

These investments reflect Epigral's ongoing commitment to building an integrated manufacturing platform and diversifying its portfolio to deliver long-term stakeholder value" Mr Patel added.

The key performance highlights:

Q1FY27 Key Highlights:

- YoY sales volume grew by 5% and overall plant utilization stood above 80%
- Revenue stood at ₹ 709 Crore, a 15% growth, due to volume growth and improved realization
- Absolute EBITDA grew by 10% to ₹ 179 Crore vs ₹ 163 Crore in Q1FY26. EBITDA margin stood at 25%
- PAT rose by 25% to ₹ 99 Crore vs ₹ 79 Crore in Q1FY26. PAT margin stood at 14%
- ROCE stood at 16% in Q1FY27 compared to 24% in Q1FY26 due to lower EBIT (Earnings before Interest and Tax) in TTM (Trailing Twelve Months) and a sizeable Capital Work in Progress
- Net Debt/EBITDA stood at 0.8x as on 30th June 2026

Q1FY27 Strategic Highlights:

- Epigral's board approved capex in below two projects, which are expected to commission by H2FY28
    - Epoxy Resin & Formulations plant with capacity of 1,25,000 TPA
    - Multi-Purpose Plant (MPP) downstream for Epichlorohydrin (ECH) and Chlorotoluene Value Chain
- Epigral is also setting up pilot plant for Epoxy Resin & Formulations and MPP to optimise manufacturing process, validate product quality and facilitate customer approvals ahead of commercial scale production
- Capex of enhancing CPVC Resin, ECH and Wind Solar Hybrid Power Plant capacity are moving as per schedule and are expected to get commissioned within the timeline and budget

About Epigral Limited

Established in 2007, Epigral Limited is a premier integrated chemical manufacturer in India, operating a highly automated and infrastructure-rich manufacturing complex at Dahej, Gujarat. As a pioneer in the domestic chemical industry, the company commissioned India's first Epichlorohydrin (ECH) plant, established the country’s first Chlorotoluenes Value Chain facility, and operates India’s largest CPVC resin production capacity.

The company’s portfolio includes key products such as Caustic Soda, Caustic Potash, Chloromethanes, Hydrogen Peroxide, CPVC, Epichlorohydrin, and Chlorotoluenes Value Chain. With its planned entry into Epoxy Resin & Formulations and setting up MPP, Epigral is further strengthening its presence in advanced materials and specialty chemicals aligned with growing domestic demand.

Driven by operational excellence and sustainable manufacturing, Epigral continues to focus on high-value specialty chemical expansion through its integrated manufacturing capabilities and dedicated R&D centre in Ahmedabad, creating long-term value for customers, partners, and stakeholders.